Clinical trials: Neutralizing Antibody
HIV Infections
A Study to Evaluate the Antiviral Effect, Safety and Tolerability of GSK3810109A in Viremic Human Immunodeficiency Virus (HIV)-1 Infected Adults
This study is to evaluate antiviral activity, efficacy, safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of GSK3810109A in HIV-1 infected treatment naive adults.
- Trial name
- NCT04871113
- Testing
- GSK3810109A, Dolutegravir+lamivudine SOC regimen
- Where
- 24 sites in United States, Argentina and 4 more
- Volunteers
- 62 people
- Sponsor
- ViiV Healthcare
Hepatocellular Carcinoma (HCC)
A Trial to Evaluate the Safety and Efficacy of the Combination of the Oncolytic Immunotherapy Pexa-Vec With the PD-1 Receptor Blocking Antibody Nivolumab in the First-line Treatment of Advanced Hepatocellular Carcinoma (HCC)
This is a study to Evaluate the Safety and Efficacy of the Combination of the Oncolytic Immunotherapy Pexa-Vec With the PD-1 Receptor Blocking Antibody Nivolumab in the First-line Treatment of Advanced Hepatocellular Carcinoma…
- Trial name
- NCT03071094
- Testing
- Pexastimogene Devacirepvec (Pexa Vec), Nivolumab
- Where
- 2 sites in France
- Volunteers
- 14 people
- Sponsor
- Transgene
HIV-1-infection
Study of Lenacapavir, Teropavimab, and Zinlirvimab in Virologically Suppressed Adults With HIV-1 on Stable Oral Treatment Regimens
The goal of this clinical study is to compare how effective a long-acting treatment of injectable combination of lenacapavir (LEN), teropavimab (TAB), and zinlirvimab (ZAB) is versus continuing a daily oral HIV treatment in…
- Trial name
- NCT07683000
- Testing
- Lenacapavir, Lenacapavir Tablet, Teropavimab
- Where
- 2 sites in United States
- Volunteers
- 590 people
- Sponsor
- Gilead Sciences
Advanced Solid Tumor
A Dose Escalation and Expansion Study of NB002 in Participants With Advanced or Metastatic Solid Tumors
This study is a first-in-human, multicenter, open label, uncontrolled, non-randomized, phase 1a/1b study, to evaluate the safety, tolerability, and preliminary antitumor activity of NB002 in subjects with advanced solid tumors.
- Trial name
- NCT05924906
- Testing
- NB002
- Volunteers
- 30 people
- Sponsor
- Suzhou Neologics Bioscience Co., Ltd.
Rabies Virus Infection
Safety, Pharmacokinetics, and Pharmacodynamic Testing of Rabies mAb CBB 1
rabies mab CBB 1 is mainly used for passive immunization of patients bitten or scratched by rabies or other animals carrying rabies virus, this study mainly studies the safety, tolerability, pharmacokinetics, neutralizing…
- Trial name
- NCT05832073
- Testing
- Natural full human monoclonal antibody CBB 1 injection, Rabies Human Immunoglobulin (HRIG), Lyophilized rabies vaccine for human use (Vero cells)
- Where
- China
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- Changchun BCHT Biotechnology Co.
Tetanus
Study to Compare the Anti-tetanus Neutralizing Antibody Titers and Safety of TNM002 Injection With Human Tetanus Immunoglobulin or Placebo in Adult Volunteers
The primary objective is to compare the anti-tetanus neutralizing antibody titers of TNM002 Injection with human tetanus immunoglobulin (HTIG) following a single intramuscular (IM) injection in Chinese adult volunteers.
- Trial name
- NCT05625477
- Testing
- TNM002 (low dose), TNM002 (medium dose), TNM002 (high dose)
- Where
- 4 sites in China
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Zhuhai Trinomab Pharmaceutical Co., Ltd.
Covid19
Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants
The primary purpose of this study is to investigate the safety and tolerability of BGB-DXP593 administered intravenously as a single dose in healthy participants
- Trial name
- NCT04532294
- Testing
- BGB DXP593
- Where
- Australia
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- BeiGene
Non Small Cell Lung Cancer, Solid Tumor
SHP2 Inhibitor BBP-398 in Combination With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With a KRAS Mutation
This is a Phase 1 study of BBP-398, a SHP2 inhibitor, in combination with nivolumab, a PD-1 antibody, in patients with NSCLC with a KRAS mutation. The study involves 2 parts: Phase 1a Dose Escalation and Phase 1b Dose Expansion.
- Trial name
- NCT05375084
- Testing
- BBP-398 with nivolumab
- Where
- 15 sites in United States
- Volunteers
- 21 people
- Sponsor
- Navire Pharma Inc., a BridgeBio company
HIV-1 Infection
Study to Evaluate the Safety and Efficacy of Teropavimab and Zinlirvimab in Combination With Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection
The primary objective of this study is to evaluate the safety and tolerability of a combination of the broadly neutralizing antibodies (bNAbs) teropavimab (formerly GS-5423) and zinlirvimab (formerly GS-2872) in combination with…
- Trial name
- NCT04811040
- Testing
- Oral Lenacapavir, Subcutaneous Lenacapavir, Teropavimab
- Where
- 23 sites in United States
- Volunteers
- 32 people
- Sponsor
- Gilead Sciences
Human Papillomavirus Infection
Long-term Immune Persistence of a Bivalent HPV Vaccine in Females From Study 311-HPV-1004
This long-term extension study evaluates the persistence of neutralizing antibody responses to a bivalent human papillomavirus vaccine in females who previously participated in study 311-HPV-1004 (NCT02740777).
- Trial name
- NCT07820241
- Testing
- Bivalent Human Papillomavirus Vaccine (Types 16 and 18, Pichia pastoris)
- Where
- 2 sites in China
- Volunteers
- 348 people, healthy volunteers welcome
- Sponsor
- Shanghai Zerun Biotechnology Co.,Ltd
Multiple Sclerosis
Safety of Avonex Treatment in Multiple Sclerosis Patients With Neutralizing Antibodies to Interferon Beta Therapy
This study is to find out the safety and effectiveness of Avonex (interferon-beta-1a) Therapy in patients who have developed neutralizing antibodies during previous interferon-beta treatment
- Trial name
- SAFE (NCT00493077)
- Testing
- low immunogenic interferon-beta-1a
- Where
- 5 sites in Sweden
- Volunteers
- 3 people
- Sponsor
- Biogen
Solid Tumor, Adult
First-in-Human Study of the GDF-15 Neutralizing Antibody Visugromab (CTL-002) in Patients With Advanced Cancer (GDFATHER)
The Phase 1 part (Part A) is a dose escalation study of IV visugromab (CTL-002, a monoclonal antibody neutralizing GDF-15) as monotherapy and in combination with an approved checkpoint inhibitor (CPI) in patients with advanced…
- Trial name
- GDFATHER (NCT04725474)
- Testing
- visugromab (CTL-002), nivolumab
- Where
- 13 sites in Germany, Spain and 1 more
- Volunteers
- 199 people
- Sponsor
- CatalYm GmbH
Rabies
Randomized Phase II Trial on Safety and Neutralizing Activity of CL184 and Rabies Vaccine Versus Human Rabies Immune Globulin (HRIG) and Rabies Vaccine in Children and Adolescents
The aim of this study is to evaluate the safety of the monoclonal antibody cocktail CL184 in combination with rabies vaccine compared with human rabies immune globulin (HRIG) in combination with rabies vaccine in healthy children…
- Trial name
- NCT00708084
- Testing
- CL184, HRIG
- Where
- Philippines
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Crucell Holland BV
HIV -1 Infection
HIV-1 Virologic Suppression With TMB-365 and TMB-380 Antibodies Study
TMB-365 is a monoclonal antibody that binds to the CD4 receptor. TMB-380, aka VRC07-523LS is a monoclonal antibody that binds to HIV. Both interfere with HIV entry.
- Trial name
- VISTA (NCT07215468)
- Testing
- TMB-365, TMB-380, Baseline ART
- Where
- 10 sites in United States
- Volunteers
- 88 people
- Sponsor
- TaiMed Biologics Inc.
HIV-1 Infection
A Study of Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection
The goal of this study is to test the effectiveness, safety, and tolerability of the combination of broadly neutralizing antibodies (bNAbs) (teropavimab (TAB; GS-5423) and zinlirvimab (ZAB; GS-2872)) with lenacapavir (LEN) in…
- Trial name
- NCT05729568
- Testing
- Teropavimab, Zinlirvimab, Lenacapavir Tablet
- Where
- 34 sites in United States, Australia and 2 more
- Volunteers
- 83 people
- Sponsor
- Gilead Sciences
Amyotrophic Lateral Sclerosis
Multiple Doses of AT-1501-A201 in Adults With ALS
This is a Phase 2a, multi-center, open label, multiple dose study of AT-1501, a humanized monoclonal antibody antagonist to CD40 ligand (CD40L).
- Trial name
- NCT04322149
- Testing
- AT-1501
- Where
- 13 sites in United States, Canada
- Volunteers
- 54 people
- Sponsor
- Anelixis Therapeutics, LLC
Mucopolysaccharidosis (MPS), Hunter Syndrome
A Study of ELAPRASE in Treatment-naïve Participants With Hunter Syndrome (Mucopolysaccharidosis [MPS] II)
The main aim of this study is to evaluate the ability of a prophylactic immune tolerizing regimen (ITR) to prevent or reduce the development of high titer anti-idursulfase antibodies in treatment-naïve participants with Hunter…
- Trial name
- NCT05494593
- Testing
- ELAPRASE, Rituximab, Methotrexate
- Where
- 8 sites in United States
- Sponsor
- Takeda
Smoldering Multiple Myeloma
Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma
This study will assess the antimyeloma effects of BHQ880A in patients with smoldering multiple myeloma with high risk of progression to active multiple myeloma.
- Trial name
- NCT01302886
- Testing
- BHQ880
- Where
- 13 sites in United States, France and 1 more
- Volunteers
- 41 people
- Sponsor
- Novartis Pharmaceuticals
Solid Tumors
Safety and Pharmacokinetics Study of YYB101 in Advanced Solid Tumors Patients Who Are Refractory to Standard Therapy
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and maximum tolerated dose (MTD) of YYB101, HGF-neutralizing humanized Mab, in advanced solid tumors patients who are refractory to standard…
- Trial name
- NCT02499224
- Testing
- YYB101
- Where
- South Korea
- Volunteers
- 39 people
- Sponsor
- CellabMED
Household Contacts
A Study to Evaluate AAV9 Neutralizing Antibody Seroconversion in Household Contacts.
This study will include male and female participants who live or work in the same household as a patient in one of the fordadistrogene movaparvovec interventional studies.
- Trial name
- NCT04543357
- Testing
- Blood Draw
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Pfizer